ALT PE Ratio & Valuation,Is ALT Overvalued — Intellectia
ALT Relative Valuation
ALT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ALT is overvalued; if below, it's undervalued.
Historical Valuation
Altimmune Inc(ALT) is now in theOvervaluedzone, suggesting that its currentforward PSratio of152745.66is consideredOvervaluedcompared with the five-year average of-5.71.The fair price ofAltimmune Inc(ALT)is between0.25to4.35according to relative valuation methord. Compared to the current price of 5.23 USD, Altimmune Inc isOvervalued By 20.1%.
Relative Value
Fair Zone
0.25-4.35
Current Price：5.23
20.1%
Overvalued
-4.63
PE
1Y
3Y
5Y
Trailing
Forward
-3.10
EV/EBITDA
Altimmune Inc. (ALT) has a current EV/EBITDA of -3.10. The 5-year average EV/EBITDA is -2.73. The thresholds are as follows: Strongly Undervalued below -6.44, Undervalued between -6.44 and -4.59, Fairly Valued between -0.88 and -4.59, Overvalued between -0.88 and 0.98, and Strongly Overvalued above 0.98. The current Forward EV/EBITDA of -3.10 falls within the Historic Trend Line -Fairly Valued range.
-2.93
EV/EBIT
Altimmune Inc. (ALT) has a current EV/EBIT of -2.93. The 5-year average EV/EBIT is -3.01. The thresholds are as follows: Strongly Undervalued below -7.34, Undervalued between -7.34 and -5.17, Fairly Valued between -0.84 and -5.17, Overvalued between -0.84 and 1.32, and Strongly Overvalued above 1.32. The current Forward EV/EBIT of -2.93 falls within the Historic Trend Line -Fairly Valued range.
152745.66
PS
Altimmune Inc. (ALT) has a current PS of 152745.66. The 5-year average PS is 27348.83. The thresholds are as follows: Strongly Undervalued below -77579.75, Undervalued between -77579.75 and -25115.46, Fairly Valued between 79813.11 and -25115.46, Overvalued between 79813.11 and 132277.40, and Strongly Overvalued above 132277.40. The current Forward PS of 152745.66 falls within the Strongly Overvalued range.
-7.11
P/OCF
Altimmune Inc. (ALT) has a current P/OCF of -7.11. The 5-year average P/OCF is -1.58. The thresholds are as follows: Strongly Undervalued below -41.87, Undervalued between -41.87 and -21.73, Fairly Valued between 18.57 and -21.73, Overvalued between 18.57 and 38.72, and Strongly Overvalued above 38.72. The current Forward P/OCF of -7.11 falls within the Historic Trend Line -Fairly Valued range.
-5.63
P/FCF
Altimmune Inc. (ALT) has a current P/FCF of -5.63. The 5-year average P/FCF is -5.47. The thresholds are as follows: Strongly Undervalued below -10.39, Undervalued between -10.39 and -7.93, Fairly Valued between -3.01 and -7.93, Overvalued between -3.01 and -0.55, and Strongly Overvalued above -0.55. The current Forward P/FCF of -5.63 falls within the Historic Trend Line -Fairly Valued range.
Altimmune Inc (ALT) has a current Price-to-Book (P/B) ratio of 2.71. Compared to its 3-year average P/B ratio of 2.62 , the current P/B ratio is approximately 3.25% higher. Relative to its 5-year average P/B ratio of 2.46, the current P/B ratio is about 10.13% higher. Altimmune Inc (ALT) has a Forward Free Cash Flow (FCF) yield of approximately -12.07%. Compared to its 3-year average FCF yield of -22.70%, the current FCF yield is approximately -46.83% lower. Relative to its 5-year average FCF yield of -20.54% , the current FCF yield is about -41.23% lower.
2.71
P/B
Median3y
2.62
Median5y
2.46
-12.07
FCF Yield
Median3y
-22.70
Median5y
-20.54
Competitors Valuation Multiple
The average P/S ratio for ALT's competitors is 25470.39, providing a benchmark for relative valuation. Altimmune Inc Corp (ALT) exhibits a P/S ratio of 152745.66, which is 499.7% above the industry average. Given its robust revenue growth of 0.00%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ALT decreased by 26.91% over the past 1 year. The primary factor behind the change was an decrease in Revenue Growth from 5.00K to 5.00K.
The secondary factor is the P/E Change, contributed -10.14%to the performance.
Overall, the performance of ALT in the past 1 year is driven by Revenue Growth. Which is more sustainable.
Is Altimmune Inc (ALT) currently overvalued or undervalued?
Altimmune Inc(ALT)is now in theOvervaluedzone, suggesting that its currentforward PSratio of 152745.66is consideredOvervaluedcompared with the five-year average of-5.71.The fair price of Altimmune Inc(ALT)is between0.25to4.35according to relative valuation methord. Compared to the current price of5.23USD, Altimmune Inc isOvervalued By 20.10% .
What is Altimmune Inc (ALT) fair value?
ALT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Altimmune Inc (ALT) is between 0.25to4.35 according to relative valuation methord.
How does ALT's valuation metrics compare to the industry average?
The average P/S ratio for ALT's competitors is 25470.39, providing a benchmark for relative valuation. Altimmune Inc Corp (ALT) exhibits a P/S ratio of 152745.66, which is 499.70% above the industry average. Given its robust revenue growth of 0.00%, this premium appears unsustainable.
What is the current P/B ratio for Altimmune Inc (ALT) as of Dec 15 2025?
As of Dec 15 2025, Altimmune Inc (ALT) has a P/B ratio of 2.71. This indicates that the market values ALT at 2.71 times its book value.
What is the current FCF Yield for Altimmune Inc (ALT) as of Dec 15 2025?
As of Dec 15 2025, Altimmune Inc (ALT) has a FCF Yield of -12.07%. This means that for every dollar of Altimmune Inc’s market capitalization, the company generates -12.07 cents in free cash flow.
What is the current Forward P/E ratio for Altimmune Inc (ALT) as of Dec 15 2025?
As of Dec 15 2025, Altimmune Inc (ALT) has a Forward P/E ratio of -4.63. This means the market is willing to pay $-4.63 for every dollar of Altimmune Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Altimmune Inc (ALT) as of Dec 15 2025?
As of Dec 15 2025, Altimmune Inc (ALT) has a Forward P/S ratio of 152745.66. This means the market is valuing ALT at $152745.66 for every dollar of expected revenue over the next 12 months.
